---
title: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <em>RET</em>
  Fusion-Positive NSCLC
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870973/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231024180819&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Treatment with selpercatinib led to significantly longer
  progression-free survival than platinum-based chemotherapy with or without pembrolizumab
  among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and
  others; ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, ...